8-K filing — PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)

Pacific Biosciences of California, Inc. Announces $100 Million At-the-Market Equity Offering

Pacific Biosciences of California, Inc. has entered into a sales agreement with Allen & Company to sell up to $100 million of its common stock through an at-the-market offering.

UBS Maintains Neutral on Pacific Biosciences, Lowers Price Target to $2.7

UBS Adjusts Price Target on Pacific Biosciences of California

UBS has lowered its price target for Pacific Biosciences of California, Inc. while maintaining a Neutral rating on the stock.

PacBio Reports Third-Quarter 2026 Financial Results and Restructuring

PacBio reported its third-quarter 2026 financial results, showing a 6% year-over-year revenue increase and a workforce reduction of approximately 8%.

Barclays Maintains Underweight Rating on PacBio, Raises Price Target

Barclays maintained its Underweight rating on Pacific Biosciences and increased its price target from $1.25 to $2.00.

Piper Sandler Maintains Neutral Rating on PacBio, Raises Price Target

Piper Sandler maintained its Neutral rating on Pacific Biosciences and increased its price target from $2.00 to $3.00.